Parallax Volatility Advisers’s Sage Therapeutics SAGE Stock Holding History

Parallax Volatility Advisers’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-86,000	Closed	-$1.86M	–	2280
2023 Q4	$1.86M	Buy	86,000 +72,500	+537%	+$1.44M	﹤0.01%	1193
2023 Q3	$278K	Buy	+13,500	New	+$390K	﹤0.01%	1741
2021 Q3	–	Sell	-34,000	Closed	-$1.93M	–	3363
2021 Q2	$1.93M	Buy	+34,000	New	+$2.4M	﹤0.01%	1648
2019 Q4	–	Sell	-14,800	Closed	-$2.08M	–	2609
2019 Q3	$2.08M	Sell	14,800 -3,000	-17%	-$502K	﹤0.01%	1123
2019 Q2	$3.26M	Hold	17,800	–	–	﹤0.01%	885
2019 Q1	$2.83M	Buy	17,800 +3,000	+20%	+$434K	﹤0.01%	877
2018 Q4	$1.42M	Hold	14,800	–	–	﹤0.01%	1197
2018 Q3	$2.09M	Buy	+14,800	New	+$2.28M	﹤0.01%	1008
2018 Q2	–	Sell	-20,000	Closed	-$3.22M	–	3128
2018 Q1	$3.22M	Buy	+20,000	New	+$3.4M	﹤0.01%	638
2017 Q4	–	Sell	-50,100	Closed	-$3.12M	–	4771
2017 Q3	$3.12M	Buy	50,100 +100	+0.2%	+$7.85K	0.01%	706
2017 Q2	$3.98M	Buy	+50,000	New	+$3.61M	0.01%	629

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Parallax Volatility Advisers's SAGE Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Sage Therapeutics (SAGE) in Q4 2022, closing a stake of 7,386 shares — an estimated $289K sold.

Parallax Volatility Advisers first reported a position in SAGE in Q2 2017 and held it in 10 quarters. The position peaked at $1.92M in Q4 2018. 206 funds tracked by Wall St. Rank hold SAGE as of Q4 2022.

Parallax Volatility Advisers reported no remaining Sage Therapeutics position as of Q4 2022 after selling out during the quarter.
Parallax Volatility Advisers sold 7,386 Sage Therapeutics shares in Q4 2022, an estimated $289K.
Parallax Volatility Advisers first reported a position in Sage Therapeutics in Q2 2017 and held it in 10 quarters.
Parallax Volatility Advisers's Sage Therapeutics position peaked at $1.92M in Q4 2018.
206 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.